Disc Medicine, Inc. Reviews ASH Meeting Data and Operational Plans
I'm PortAI, I can summarize articles.
Disc Medicine, Inc. presented at the ASH Annual Meeting on Dec 7, 2025, highlighting Bitopertin's NDA acceptance and potential launch by Jan 2026. DISC-0974 shows promise in treating anemia of myelofibrosis, while a Phase 2 study for DISC-3405 in polycythemia vera is ongoing. The company is funded until 2029, supporting key milestones, and Bitopertin is selected for FDA's CNPV program for expedited review.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments